Literature DB >> 20367527

Nervous system adverse responses to topiramate in the treatment of neuropsychiatric disorders.

Jurjen J Luykx1, Johannes A Carpay.   

Abstract

IMPORTANCE OF THE FIELD: Nervous system adverse drug reactions (NS-ADRs), such as cognitive complaints and paresthesia, are among the most frequent and clinically important ADRs of topiramate. Studying ADR profiles across disorders is clinically relevant because treatment decision-making in neuropsychiatry is highly guided by ADR profiles. AREAS COVERED IN THIS REVIEW: We used medline searches (until July 2009) to review the NS-ADRs of topiramate across the most investigated topiramate indications: alcohol dependence, essential tremor, binge-eating disorder, bulimia nervosa, migraine and epilepsy. We compared NS-ADRs between these disorders but did not carry out meta-analysis. WHAT THE READER WILL GAIN: ADR profiles greatly differed between disorders. Drop-outs due to ADRs highly varied between disorders: from 2% in the bulimia nervosa group to 29% in the migraine group. Paresthesia was the most common NS-ADR for all disorders but frequencies also differed between disorders. Cognitive complaints were frequent and were reported in comparable proportions. TAKE HOME MESSAGE: When prescribing topiramate in neuropsychiatry, physicians should be aware that NS-ADR profiles have been found to differ between disorders. Differences in drop-out rates due to ADRs and in frequencies of specific NS-ADRs across disorders must be taken into account when evaluating the potential harm of topiramate in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367527     DOI: 10.1517/14740331003739196

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  3 in total

Review 1.  Treatment of clozapine-associated weight gain: a systematic review.

Authors:  Z Whitney; R M Procyshyn; D H Fredrikson; A M Barr
Journal:  Eur J Clin Pharmacol       Date:  2015-01-28       Impact factor: 2.953

2.  Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study.

Authors:  Thomas Paparrigopoulos; Elias Tzavellas; Dimitris Karaiskos; Georgia Kourlaba; Ioannis Liappas
Journal:  BMC Psychiatry       Date:  2011-03-14       Impact factor: 3.630

3.  Topiramate precipitating a manic episode in a bipolar patient comorbid with binge eating disorder: A case report.

Authors:  Jinfeng Duan; Jianbo Lai; Dandan Wang; Weihua Zhou; Manli Huang; Shaohua Hu; Yi Xu; Jing Lu
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.